U.S. FDA Approves TECVAYLI (Teclistamab-Cqyv), The First Bispecific T-Cell Engager Antibody For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma'

Press/Media

Period25 Oct 2022

Media coverage

1

Media coverage

  • TitleU.S. FDA Approves TECVAYLI (Teclistamab-Cqyv), The First Bispecific T-Cell Engager Antibody For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma'
    Media name/outletMENAFN -Press Releases (English)
    Country/TerritoryJordan
    Date25/10/22
    PersonsAjai Chari
View all 1
View less